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Abstract
15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2), a peroxisome proliferator-activated receptor-
γ (PPAR-γ) agonist, has physiological properties including pronounced anti-inflammatory
activity, though it binds strongly to serum albumin. The use of solid lipid nanoparticles (SLN)
can improve therapeutic properties increasing drug efficiency and availability. 15d-PGJ2-
SLN was therefore developed and investigated in terms of its immunomodulatory potential.
15d-PGJ2-SLN and unloaded SLN were physicochemically characterized and experiments
in vivo were performed. Animals were pretreated with 15d-PGJ2-SLN at concentrations of 3,
10 or 30 μgkg-1 before inflammatory stimulus with carrageenan (Cg), lipopolysaccharide
(LPS) or mBSA (immune response). Interleukins (IL-1β, IL-10 and IL-17) levels were also
evaluated in exudates. The 15d-PGJ2-SLN system showed good colloidal parameters and
encapsulation efficiency of 96%. The results showed that the formulation was stable for up
to 120 days with low hemolytic effects. The 15d-PGJ2-SLN formulation was able to reduce
neutrophil migration in three inflammation models tested using low concentrations of 15d-
PGJ2. Additionally, 15d-PGJ2-SLN increased IL-10 levels and reduced IL-1β as well as
IL-17 in peritoneal fluid. The new 15d-PGJ2-SLN formulation highlights perspectives of a
potent anti-inflammatory system using low concentrations of 15d-PGJ2.
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Introduction
Drug delivery systems have been developed to prolong and improve drug action while reducing
toxicity, thus overcoming common problems such as poor solubility in water [1,2].
Solid lipid nanoparticles (SLN), submicron lipid carriers sized between 50 and 1000 nm, are
composed of biocompatible materials able to incorporate mainly lipophilic drugs. SLN are consti-
tuted by an external phase (an emulsifier and water) and an inner layer composed of lipid matrix,
where the drug is dispersed [3–5]. Such nanocarriers feature low toxicity and cause no irritation
to tissues, hence the growing interest in their use in the treatment of inflammatory diseases [6].
Inflammation is an organic response that precedes tissue injury or infection. This physiolog-
ical process involves a coordinated action between the immune system and the damaged tissue,
which stimulates infiltration and subsequent activation of inflammatory cells with release of
cytokines and other mediators [7]. In such scenario, 15-deoxy-Δ12, 14-prostaglandin J2 (15d-
PGJ2) stands out as a potential anti-inflammatory molecule. This kind of prostaglandin is a
PPAR-γ (peroxisome proliferator-activated receptor-γ) agonist and it is derived from the
cyclooxygenase pathway, participating in the resolution phase of acute inflammation [8–10].
Studies have shown that PPAR-γ agonists are being used in inflammatory disorders because
they are able to regulate the immune response [9–14]. In a previous study, it was demonstrated that
1 mgkg-1 of plain 15d-PGJ2 is required to reduce neutrophil migration to an inflammation site [12]
due to the high affinity of such molecule to serum proteins [8]. In order to increase the bioaviability
and improve the pharmacological properties of 15d-PGJ2, our group demonstrated that PLGA-
encapsulated 15d-PGJ2 achieved the same therapeutic effect as free 15d- PGJ2 in several inflamma-
tion models at a concentration 33 times lower than the latter [15]. Encapsulated 15d-PGJ2 was also
able to inhibit bone loss in periodontal disease secondary to reduced gingival inflammation [16].
Such findings highlight the promising applications of 15d- PGJ2 encapsulated in nanoparticles.
The new formulation addressed in this study has advantages over other colloidal nanocarriers
such as polymeric nanoparticles. Besides being made of physiologically well-tolerated materials,
SLN have been approved for human use based on their low toxicity, reportedly 10 to 100 times
lower than polymeric nanoparticles. SLN also have good stability and wide range of administra-
tion routes, including parenteral [3,5]. SLN are produced from lipids that are solid at room tem-
perature such as mono-, di- or triglycerides, fatty acids or waxes. Such lipids are stabilized by one
or a mixture of emulsifiers to prevent nanoparticle agglomeration. Most such materials are cur-
rently used in pharmaceutical or cosmetic formulations, which highlights their low toxicity [17].
SLN have shown to be better tolerated in vivo than polymeric nanoparticles, since the poly-
mers used in the latter may carry an intrinsic element of cytotoxicity [18,19]. Moreover, the
composition of the formulation used in this study, namely tripalmitin as lipid matrix and PVA
as emulsifier, has been shown to be suitable as a sustained delivery system of bioactive mole-
cules due to their good physicochemical characteristics such as size, zeta potential, high encap-
sulation efficiency, etc [20,21].
There have only been a few reports on the association of 15d-PGJ2 to lipid systems [22],
though none amounted to a study in vivo on the anti-inflammatory activity of such systems.
The purpose of this study was therefore to address the physicochemical properties and the
potential anti-inflammatory activity of the novel 15d-PGJ2-SLN formulation in vivo.
Materials and Methods
Preparation of 15d-PGJ2-Loaded SLN
The nanoparticles were prepared via the emulsification/solvent evaporation method described
elsewhere [21,23], with some modifications. Firstly, the organic phase composed by the lipid
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glyceryl tripalmitate (150 mg) and 15d-PGJ2 (100 μg) was dissolved in chloroform (5 mL). The
aqueous phase was composed by polyvinyl alcohol (1%, w/v) and deionized water (30 mL).
The organic phase was added to the aqueous phase and this mixture was sonicated for 5 min at
40 W on a probe sonicator yielding an emulsion, which in turn was mixed on an Ultra Turrax
homogenizer at 18,000 rpm for 7 min. The organic solvent was eliminated under low pressure
using a rotating evaporator and the final volume was 16 mL of 15d-PGJ2 at a concentration of
6.25 μg.mL-1. A control formulation was also prepared without 15d-PGJ2.
Encapsulation Efficiency of 15d-PGJ2
The amount of 15d-PGJ2 encapsulated by the SLN system was determined by ultrafiltration/
centrifugation using Amicon1 ultrafiltration devices (10 kDa MWCO; Millipore1). 15d-PGJ2-
SLN suspensions were centrifuged and the filtrate was analyzed using high performance liquid
chromatography (HPLC). 15d-PGJ2 was quantified in a Varian ProStar equipment (Agilent
1
Technologies), PS210 isocratic pump and a UV-Vis detector operating at 205 nm. A Gemini1
C18 column NX 5μ C18 110 Å, 150 x 4.6 mm (Phenomenex
1) was used for the mobile phase of
sodium phosphate monobasic solution (pH 3.5; 0.01M) and acetonitrile (58:42, v/v) at 1 mL.
min-1. The sample injection volume was 100 μL [15]. Encapsulation efficiency was then deter-
mined from the difference between 15d-PGJ2 concentration measured in the ultrafiltrate and
its total concentration (100%) in the nanoparticle suspension.
Size, Polydispersion, Zeta Potential and pH Measurements
The hydrodynamic diameter and polydispersion (PI) of nanoparticles were determinated using
dynamic light scattering and the zeta potential was evaluated by microeletrophoresis. A ZetaSi-
zer Nano ZS 90 analyzer (Malvern1 Instruments) was used to perform the measurements
(25°C, with an angle of 90°) with a dilution factor of 100 times. The pH values of the suspen-
sions were evaluated using a calibrated pHmeter (Tecnal1, Brazil). The results were shown as
the means of five measures (mean ± SD). The physicochemical stability of the nanoparticles
was evaluated as a function of time, analyzing the suspension over 120 days [15,21,24].
Nanoparticle Tracking Analysis (NTA)
SLN size distribution was investigated through NTA. The analyses were carried out on a Nano-
Sight LM 10 instrument system, green laser beam (532 nm) and sCMOS camera, all controlled
via dedicated NanoSight v.2.3 software (Malvern1 Instruments, UK). Samples were diluted
10,000 times and analyzed in triplicate injecting the sample (1 mL) into the cell. Five individual
videos of Brownian motion were recorded for each replicate at two thousand particles per repli-
cate. Finally, the result achieved was the concentration of the particles as a function of size dis-
tribution [20,21].
Determination of Nanoparticle Morphology
Nanoparticle morphology was determined using transmission electron microscopy (TEM).
SLN suspensions with or without the drug were diluted and applied to copper grids
(200-mesh) coated with carbon film. The samples were dried at room temperature and were
contrasted using uranyl acetate (2%) and analyzed using a Zeiss LEO 906 microscope operating
at 80 kV, preserving the nanoparticle morphology [21,25].
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In Vitro Release Assay
The release profile of encapsulated 15d-PGJ2 in SLN was evaluated employing a donor-accep-
tor compartments system, with an interposed cellulose membrane (MWCO 1 kDa). The sys-
tem was maintained under constant magnetic stirring and sink conditions. Samples were
applied to the surface of the donor compartment. From the acceptor compartment, aliquots of
1 mL were collected over 6 hours. The concentration of the drug released was determined by
HPLC in the acceptor compartment. The experiment was carried out in triplicate [16,24].
The release mechanism of SLN-encapsulated 15d-PGJ2 was evaluated using the Baker-Lons-
dale theoretical model. This is based on the Higuchi model and is intended at elucidating drug
release phenomena from spherical devices, such as micro and nanoparticles [26].
Evaluation of Cellular Viability
Cell viability experiment was established using the MTT reduction test. The experiment was
performed on Balb-c 3T3 fibroblasts cultured in DMEM (supplemented with 10% fetal bovine
serum, 1% penincilin and streptomycin sulfate). Briefly, cells were seeded into culture plates
and incubated for 48 h. They were then exposed to free 15d-PGJ2 and SLN suspension (with
and without 15d-PGJ2) at drug concentrations ranging from 0.06 to 2.2 μg.mL
-1 for 24 hours.
The cells were then incubated with MTT for 2 h at 37°C and purple formazan was quantified
using a plate reader at 570 nm. Cell viability was calculated as absorbance of converted dye
[20,21,24].
Animals
Male Balb/c mice (20–25 g) were used in this investigation. The animals were maintained in a
temperature-controlled room (12:12 h light–dark cycle) and provided water and food ad libi-
tum. This study was approved by the Ethics Committee on Animal Research of the University
of Campinas (registration number 3623-1/2015) and all animals were manipulated in accor-
dance with the Guiding Principles for the Care and Use of Animals.
Antigen-Induced Peritonitis
The immunization procedure occurred as previously described [15]. On day one, the animals
were exposed to the antigen via a subcutaneous (s.c.) injection of 100 μL of saline, 100 μL of
complete Freund’s adjuvant and 500 μg of methylated bovine serum albumin (mBSA) antigen.
The animals were boosted on days 7 and 14 with mBSA dissolved in incomplete Freund’s adju-
vant. Non-immunized (NI) animals received similar treatment, but without the antigen. All
animals were treated with 15d-PGJ2-SLN at 3, 10 or 30 μgkg-1 or empty SLN and challenged
with either mBSA (30 μg/cavity, intraperitoneal (i.p.)) or saline control on day 21. Four hours
after the mBSA challenge, the animals were sacrificed by isoflurane inhalation and the perito-
neal cavity was washed with 3 mL of phosphate buffered saline (PBS) containing 1 mM ethyle-
nediamine tetraacetic acid (EDTA) and the exudate was recovered [15,27].
Carrageenan-Induced Peritonitis and LPS-Induced Neutrophil Migration
Thirty minutes prior to the challenge, the animals were pretreated subcutaneously with 200 μL
of saline or 15d-PGJ2-SLN (3, 10 or 30 μgkg-1). Inflammation was caused by i.p. injection of
carrageenan (Cg at 500 μg/cavity in 200 μL). A control group with empty SLN was included
aiming to verify whether the vehicle alone could affect neutrophil migration. Two hundred
microliters of vehicle were injected s.c. and after 30 minutes the animals were challenged with
saline or Cg (i.p.). As previously described, 4 hours after the Cg challenge, the animals were
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sacrificed and the peritoneal cavity was washed with PBS containing 1 mM EDTA and the peri-
toneal fluid recovered [15].
For LPS-induced neutrophil migration, the animals were pretreated s.c. with saline
(200 μL), 15d-PGJ2-SLN (3, 10 or 30 μgkg-1) or empty SLN. Thirty minutes later, LPS solution
was injected (100 ng/cavity, i.p.). Four hours after the LPS challenge, all animals underwent the
same procedure described for antigen-induced and Cg-induced peritonitis [15].
Cell Counts and Cytokine Measurements
A Neubauer chamber was used for total cell counts, with samples diluted in Turk’s solution.
Differential cell counts were determined from cytocentrifuge monolayers stained with Wright-
Giemsa (100 counted cells). The results were expressed as the number of neutrophils per cavity
(means ± SD) [15].
IL-1β, IL-10 and IL-17 levels in the peritoneal fluid were determined using commercial kits
of enzyme-linked immunosorbent assay (ELISA) (R&D Systems, USA) at optical density of
490 nm. From the standard curves, the results were expressed as pgmL-1 of cytokine.
Hemolytic Assay
The hemolytic effect provoked by nanoparticle suspensions was evaluated using mouse eryth-
rocytes (0.15% hematocrit). Hemolysis percentage was determined by the quantity of hemoglo-
bin released from red blood cells. The samples were incubated with 15d-PGJ2-SLN suspensions
at concentrations ranging from 6.25 to 125 ng.mL-1 of the drug. Empty SLN were evaluated at
the same nanoparticle concentration (~1.60 X 1013 nanoparticles/mL) tested for loaded nano-
particles. Erythrocytes were incubated at 37°C for 15 min and centrifuged at 1500x g for 3 min.
Hemoglobin in the supernatant was detected at 412 nm wavelength. The data were expressed
as hemolysis percentage [15,28].
Statistical Analysis
Five animals were used per group for the experiments in vivo. Data were reported as
means ± SD. Different treatments were compared using ANOVA and Bonferroni’s t-test for
unpaired values. For the cytotoxic assays, data were analyzed using ANOVA with Tukey’s post
hoc test. Statistical significance was set at P<0.05.
Results
Both SLN suspensions (empty and 15d-PGJ2 loaded) were prepared and colloidal parameters
evaluated. The nanoparticles were measured for hydrodynamic diameter, polydispersion, zeta
potential and morphology. The rationale behind developing lipid nanoparticles includes the
relatively low costs of the raw materials and production as well as the excellent physicochemical
stability inherent of such preparations. The colloidal parameters are described in Table 1.
The results showed that the parameters evaluated for the nano suspensions were similar to
those described for colloidal suspensions and that such parameters were not affected by encap-
sulation of the active ingredient [21]. The polydispersion index values were below 0.2 for both
suspensions, indicating a narrow distribution of particle diameter; a negative zeta potential was
found for both nano suspensions. Encapsulation efficiency was up to 95%. This high value is a
combination of the lipophilicity and affinity of the drug for the lipid core.
The physicochemical stability of particles is important data to define suitability of formula-
tions. The parameters size, polydispersion, zeta potential, pH and encapsulation efficiency
were monitored over 120 days of storage in ambar glass flasks. The size of nanoparticles in
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both suspensions analyzed had such little variation that it may be regarded as constant
throughout the period of 120 days, indicating no aggregation of particles. The remaining
parameters followed suit, indicating suitable colloidal stability of the systems [20,21,29].
TEMmicrographs obtained for the SLN and 15d-PGJ2-SLN preparations are shown in Fig 1.
The nanoparticles presented a spherical shape with diameters in the range of 200–300 nm (Fig
1A–1D). The presence of agglomerates was a technical artifact that occurred secondary to sample
drying during processing for TEM analysis. Particle sizes were consistent with both the polydis-
persion index and the mean diameter values obtained with the DLS technique [21,29].
The NTA technique was used to characterize the SLN system. The results of nanoparticle
concentration are shown in Fig 2. For empty SLN, the concentration was 1.90 (± 0.35) × 1013
particles per mL with average diameter of 274.6 ± 93.5 nm. For 15d-PGJ2–SLN the concentra-
tion was 1.60 (± 0.69) × 1013 particles per mL with average diameter of 194.1 ± 61.9 nm. Both
DLS and NTA provided similar range of diameter values and particle concentration, with
monomodal size distributions. This was an indication of homogeneity of the system, which is
desirable in nanoparticulated formulations, as it reduces interferences with drug-release by
increasing stability.
The release profile of 15d-PGJ2 from SLN suspension was investigated (Fig 3). In this
model, only free molecules of the drug were able to transpose the membrane, while the nano-
particles were retained, which enabled the evaluation of the interaction between drug and
nanoparticles. 15d-PGJ2 was quantified by HPLC in aliquots collected from the acceptor.
Fig 3 illustrates the release profile of 15d-PGJ2 from the SLN system. The time taken for
50% release (t50%) was around 100 min. Evaluation of the release mechanism of 15d-PGJ2 from
the SLN systems was performed using the Baker-Lonsdale´s equation. Linear regression
resulted in correlation coefficient (r) values of 0.982, and release constant (k) values of 0.322 x
10−2 (± 0.001) min-1. Compared with the release profile of 15d-PGJ2 from PLGA nanocapsules,
the best fit was achieved using the Higuchi´s model (r = 0.972; k = 0.048 min-1/2) and the main
release mechanism involved is based on the Fick's Law of diffusion [16]. In this study, we
achieved compatibility with the Baker–Lonsdale model indicating that the mechanism involved
is also diffusion. With respect to k values, the release profile obtained from 15d-PGJ2-SLN was
lower than that from PLGA nanocapsules. This could be explained by the superior interaction
between 15d-PGJ2 and the tripalmitin used in the production of SLN [30], also demonstrated
via the encapsulation efficiency values (>95% for SLN and 77% for PLGA nanocapsules). This
high interaction caused slower release, showing that the SLN system was more suitable for the
15d-PGJ2 molecule.
Cell viability after exposure to SLN suspensions was assessed using the MTT reduction test.
The experiments were performed in 3T3 fibroblasts incubated with free 15d-PGJ2 and encap-
sulated 15d-PGJ2 (0.06–2.2μg.mL
-1). Controls using empty nanoparticles were also tested at
the same nanoparticle concentration (~ 1.60 x 1013 nanoparticles/mL).
It is known that some ionizable groups present in polymers, lipids and other components of
the suspensions could be somewhat toxic due to their interaction with cell membranes [19,31].
Table 1. Colloidal parameters of both SLN and 15d-PGJ2-SLN suspensions. Values are expressed as means ±standard deviations.
Parameters SLN (1st day) 15d-PGJ2-SLN (1
st day) SLN (120th day) 15d-PGJ2-SLN (120
th day)
Mean diameter (nm) 252.3 ± 8.7 283.6 ± 8.1 260.2 ± 4.9 289.5 ± 2.3
Polydispersion 0.105 ± 0.013 0.109 ± 0.048 0.147 ± 0.024 0.113 ± 0.017
Zeta potential (mV) -23.6 ± 0.3 -24.8 ± 0.7 -21.9± 1.1 -17.8± 0.3
pH 4.43 ± 0.06 4.41 ± 0.04 5.11 ± 0.02 5.22 ± 0.01
Encapsulation efficiency (%) - 96.8 ± 1.7 - 95.1 ± 0.8
doi:10.1371/journal.pone.0161796.t001
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The results (Fig 4) showed that SLN decreased cell viability to 70% at the highest concentration
tested. Exposure to free 15d-PGJ2 reduced cell viability to 30%, mainly at higher concentra-
tions, while exposure to the 15d-PGJ2-SLN formulation significantly increased cell viability at
prostaglandin concentrations ranging from 0.9 to 2.2 μg.mL-1 (P< 0.05).
Fig 1. Micrographs obtained through transmission electronmicroscopy. (a-b) SLN and 15d-PGJ2-SLN
at 77.500x magnification; (c-d) SLN and 15d-PGJ2-SLN at magnification 215.000x magnification. The bars
indicate image scales.
doi:10.1371/journal.pone.0161796.g001
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I.p. administration of mBSA in immunized animals significantly increased neutrophil
migration in the peritoneal cavity compared to saline or to mBSA in NI animals. Pretreatment
with encapsulated 15d-PGJ2 at three concentrations (3, 10 or 30 μgkg-1) was able to inhibit
neutrophil migration (3, 10 or 30 μgkg-1) (Fig 5A). Cg and LPS injections significantly
Fig 2. Nanoparticle concentration as a function of particle size (nm). (a) SLN and (b) 15d-PGJ2-SLN performed at 25°C (n = 5).
doi:10.1371/journal.pone.0161796.g002
Fig 3. Cumulative release profile of 15d-PGJ2–loaded SLN in vitro in aqueous solution at 25°C (n = 3).
doi:10.1371/journal.pone.0161796.g003
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increased neutrophil migration in vivo compared to saline. Similarly to mBSA, administration
of the 15d-PGJ2-SLN formulation sharply decreased neutrophil migration induced by either
stimuli (Fig 5B and 5C) (P< 0.05). Empty SLN were also tested in three models to verify
whether the nanoparticles were able to alter immune responses. The results indicate no signifi-
cant change in neutrophil migration (P> 0.05). Similar findings were previously reported for
15d-PGJ2-loaded polymeric nanocapsules [15].
IL-10 release induced by 15d-PGJ2-SLN was investigated in order to evaluate a possible reg-
ulatory effect on neutrophil migration. A dose-dependent increase in IL-10 levels was observed
in the peritoneal fluid of mice tested with 15d-PGJ2-SLN and challenged with mBSA or Cg or
LPS. For mice tested with saline or SLN, no increase in IL-10 levels were observed in either of
the three inflammation models (Fig 6A–6C).
Fig 4. Viability of Balb-c 3T3 cells using the MTT assay after exposure to free 15d-PGJ2 and both
nanosuspensions (n = 12). Data are represented as percentage of viable cells. (*a) 15d-PGJ2-SLN versus
15d-PGJ2 (ANOVA followed by Tukey test; P < 0.05).
doi:10.1371/journal.pone.0161796.g004
Fig 5. Anti-inflammatory effect of SLN and 15d-PGJ2-SLN assessed in different inflammatory models. The animals were tested using saline or 15d-
PGJ2-SLN (3, 10 or 30 μgkg−1) prior to challenging them with mBSA (30 μg/cavity) (A), Cg (500 μg/cavity) (B) or LPS (100 ng/cavity) (C). Neutrophil
migration was evaluated 4h later. Results are expressed as mean values (±SD) of 5 animals per group. Different letters indicate statistical significance
between groups (ANOVA followed by Bonferroni's t-test; P < 0.05).
doi:10.1371/journal.pone.0161796.g005
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Release of pro-inflammatory cytokines such as IL- 1β (Fig 6D–6F) and IL -17 (Fig 6G–6I)
was also evaluated since reduction in neutrophil migration could accompany a diminished
release of chemotactic agents. A dose-dependent decrease in IL-1β and IL-17 levels was
observed in the peritoneal exudate of mice tested with 15d-PGJ2-SLN and challenged with
mBSA, Cg or LPS, whereas the mice tested with saline or SLN alone showed no decrease in
cytokine levels for the inflammation models assessed.
The hemolytic effect of both loaded and unloaded SLN were investigated using red blood cells
frommice (Fig 7). Exposure of cells to both formulations demonstrated low toxicity, as illustrated
by the hemolysis values obtained even with the highest concentration tested (125 ng.mL-1)
(~18% for SLN and ~19% for 15d-PGJ2-SLN suspensions). Blood toxicity of the empty PLGA
nanocapsules and those containing 15d-PGJ2 was tested employing a hemolysis assay. The results
revealed a low toxicity of such formulations even at the highest concentration (125 ng.mL-1),
Fig 6. Influence of 15d-PGJ2-SLN (3, 10 or 30 mgkg-1) on IL-10, IL 17 and IL-1β levels in exudate. (A, D, G) mBSA (30 μg/cavity), (B, E, H) Cg (500 μg/
cavity), (C, F, I) LPS (100 ng/cavity). Results are expressed as mean values (±SD) of 5 animals per group. Different letters indicate statistical significance
between groups (ANOVA followed by Bonferroni's t-test; P < 0.05).
doi:10.1371/journal.pone.0161796.g006
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with 40% and 35% hemolysis reported for the empty and loaded nanocapsules, respectively [15],
while for the SLN suspensions (empty and loaded nanoparticles), 18.2% and 19.4%, respectively.
The hemolytic effect was therefore lower for the SLN than for the PLGA nanocapsules, conse-
quently blood-compatibility was higher for the former, though the difference between the formu-
lations was not statistically significant.
Discussion
Nanoencapsulation has gained great interest in the pharmaceutical field. Among the nanopar-
ticles used to encapsulate drugs, SLN can be highlighted due to its high stability, small size, pro-
tection of labile drugs as well a change in their release profile [32]. The SLN systems presented
good colloidal stability, as well as high affinity to the lipid matrix. The SLN system was able to
modify drug release profile and to maintain cell viability compared to the free drug. 15d-PGJ2
encapsulation reduced neutrophil migration in 3 different inflammatory models due in part to
a decrease in IL-1β and IL-17 levels as well an increase in IL-10.
The parameters mean diameter and polydispersion index remained practically constant,
with no aggregates, demonstrating the high stability of such systems over the study period.
Other critical parameter for colloidal stability is zeta potential. This parameter reflects nano-
particles surface charge. Some surfactants used in this formulation, such as PVA, however,
have a steric stabilization mechanism. In this case, the surface charge measured cannot be used
as the main stability parameter [1,20]. Nonetheless, the zeta potential values were not affected
by encapsulation of the drug, which indicates that the drug is mostly contained within the
nanoparticles. Such findings demonstrate that the physicochemical stability of the SLN suspen-
sion is highly suitable for 15d-PGJ2 encapsulation. Similar results have been reported for other
SLN suspensions [20,21,29].
As demonstrated, 15d-PGJ2 encapsulation into SLN was highly efficient (>95%), confirm-
ing the affinity of the drug to the lipid phase of the SLN. It has previously been reported that
the encapsulation efficiency of PLGA nanocapsules was approximately 77% for 15d-PGJ2 [15].
SLN has therefore been proved more suitable to encapsulate 15d-PGJ2, due probably to the
greater affinity or higher solubility of such drug in the lipids used in this study.
Fig 7. Hemolysis assay employing 0.15% hematocrit, pH 7.4 at 37°C for SLN and 15d-PGJ2-SLN suspensions (n = 6).
doi:10.1371/journal.pone.0161796.g007
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The release profile of the 15d-PGJ2-SLN formulation was evaluated using a two-compart-
ment model. Because of the low solubility of 15d-PGJ2 in water, it was not possible to investi-
gate the release profile of the free drug. Comparing with a previous report, the system 15d-
PGJ2-SLN presented a lower release profile than the drug encapsulated in polymeric nanocap-
sules [16], which is desirable and indicates a technical advantage of the latter over the former.
The cell viability pattern observed for unloaded SLN could be attributed to exposure of the
cells to residual PVA present in the formulation or even to the influence of the nanoparticle
charge. A study has shown that tripalmitin SLN reduced cell viability to 30% and this could be
attributed to the formation of aggregates and changes in nanoparticle structure leading to
reduced of cell viability [33]. Our experimental data showed that high doses (0.9–2.2 μg.mL-1)
of free 15d-PGJ2 resulted in lower cell viability than the 15d-PGJ2-loaded SLN (P<0.05). Such
protective an effect may be explained by a reduced availability of the drug secondary to a high
encapsulation efficiency and modified release profile obtained with the nanoparticles [19]. On
the other hand, taking into account the in vivo data, the dose of 10 μg.kg-1 was effective in all 3
inflammatory models. This concentration normalized by body size means that the final con-
centration was approximately 0.3 μg. From both the in vitro and in vivo findings, one may con-
clude that the effective dose used did not induce significant side effects. Thus, the results
confirmed that 15d-PGJ2 encapsulation into SLN resulted in reduced drug availability, thereby
favoring a higher percentage of viable cells.
The hemolytic effects of SLN suspensions were evaluated in mouse erythrocytes in order to
investigate blood compatibility of such formulations. Solid lipid nanoparticles are regarded as
biocompatible and biodegradable systems. This may be related to their physicochemical prop-
erties, lipid composition, etc [34]. The results herein demonstrated that both loaded and
unloaded formulations caused low hemolysis (below 20%) indicating biocompatibility. The
hemolytic effect observed was dose-dependent and could also be attributed to exposure to
residual PVA. Despite both formulations being biocompatible, SLN was superior at delivering
15d-PGJ2 in biological systems.
Comparing the present findings to those obtained with PLGA nanocapsules published pre-
viously [15], it is evident that SLN performed better than the polymeric nanocapsules.
It has been described that high doses of exogenous 15d-PGJ2 are needed to exert pharmaco-
logical effects [11,12] and encapsulation of the drug into polymeric nanocapsules was able to
protect the molecule and promote anti-inflammatory effects at low doses [15,16,35]. In this
investigation, our results showed that the 15d-PGJ2-SLN system had an anti-inflammatory
activity. In all three inflammatory models tested, 15d-PGJ2-SLN inhibited leukocyte migration
to an inflammatory site and, most importantly, 15d-PGJ2-SLN at 10 μg.kg
-1 was able to signifi-
cantly decrease neutrophil migration and pro-inflammatory cytokine levels (IL-1β and IL-17)
as well as to significantly raise IL-10 levels. Compared to previous data using free 15d-PGJ2
(1000 μg.kg-1) [12], the current formulation (15d-PGJ2-SLN) lowered the dose needed to
obtain an anti-inflammatory effect by 100 times. Additionally, compared to the previous for-
mulation tested (PLGA nanocapsules) [15], for which the effective dose was 30 μg.kg-1, this
new nanocarrier managed to further reduce the dose 3-fold, demonstrating that the SLN sys-
tem was the most effective at releasing the drug at the site of inflammation. The effect of free
15d-PGJ2 was not evaluated in this study because it has previously been established that the
free drug at such low concentration does not exert an anti-inflammatory effect [15].
The advantages of this new carrier are higher stability, lower preparation costs and higher
efficiency at releasing 15d-PGJ2 in three animal inflammation models compared to PLGA
nanocapsules, highlighting its potential as an alternative delivery method for 15d-PGJ2. The
results obtained herein open new perspectives and represent a great step towards the treatment
of inflammatory diseases using a sustained 15d-PGJ2 releasing method from nanoparticles.
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